| Mrs Hoang Buu Thai-ho, RPH | |
|
1520 Avenue J, Brooklyn, NY 11230-3708 | |
| (718) 253-8080 | |
| (718) 253-7580 |
| Full Name | Mrs Hoang Buu Thai-ho |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1520 Avenue J, Brooklyn, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003148602 | NPI | - | NPPES |
| 01803603 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 045340 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Hoang Buu Thai-ho, RPH 1520 Avenue J, Brooklyn, NY 11230-3708 Ph: (718) 253-8080 | Mrs Hoang Buu Thai-ho, RPH 1520 Avenue J, Brooklyn, NY 11230-3708 Ph: (718) 253-8080 |
News Archive
Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitest and Tamoxitest. These tests and the GeneMedRx medication management software can save lives and healthcare dollars by allowing doctors to personalize their prescribing practices in order to prevent adverse medication outcomes, including treatment failures and dangerous side effects.
The American Stroke Association and other organizations have spent the last decade changing the care delivery system for stroke in the United States. Now the focus must include greater emphasis on prevention and recovery, according to a special report published in Stroke: Journal of the American Heart Association.
The publication provides evidence of the durability and long term positive effect of Orthocell's Ortho-ATI™ tendon regeneration treatment for degenerate tendon injuries...
GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.
› Verified 4 days ago
Festus Ogunbanjo, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1402 Newkirk Ave, Brooklyn, NY 11226 Phone: 718-434-0391 | |
Mr. Jerry Gary Lucks, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 602 Brighton Beach Ave, Brooklyn, NY 11235 Phone: 718-332-3708 Fax: 718-332-5737 | |
Ms. Yvette Gindina, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1405 Avenue J, Brooklyn, NY 11230 Phone: 718-677-7290 | |
Nishad Hoque, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1527 Pitkin Ave, Zoya Pharmacy Inc, Brooklyn, NY 11212 Phone: 718-342-3911 Fax: 718-342-3988 | |
Svetlana Shlyam, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2202 Avenue U, Brooklyn, NY 11229 Phone: 347-462-4562 | |
Ms. Lily Hau, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 139 Flatbush Ave, Brooklyn, NY 11217 Phone: 718-290-1110 | |
Enza M Burns, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6101 18th Ave, Brooklyn, NY 11204 Phone: 718-236-0146 |